This is the first in a series of semi-regular columns on the Covid-19 pandemic. In this edition: CVRs at risk, new hurdles for DBV Technologies, a trial suspension for Provention, and more.
If the Food and Drug Administration slows or halts ongoing drug reviews due to the coronavirus, payout of the Bristol Myers Squibb contingent value rights might be in jeopardy.
About the Author Reprints
